Online ISSN : 1884-6440
Print ISSN : 0385-1036
ISSN-L : 0385-1036
菊池 寛
ジャーナル オープンアクセス

2009 年 34 巻 6 号 p. 328-335


It was previously considered that the practical application of liposomal medicines was very difficult. The pharmaceutical technologies for mass production, long term stability during storage, encapsulation efficiency of the drug, etc. were seemed big problems to be solved, and it was well known that the liposomal particles are apt to be entrapped in vivo by the reticuloendothelial system (RES) such as liver, spleen, etc. Fortunately, owing to the progress of science, about 10 liposomal medicines containing the anticancer agents, the antifungal agents, etc. were launched out and are now contributed to medical treatment in the world. Recently liposomes are expected to be useful as the vectors for in vivo nucleic acid (plasmid DNA, siRNA, etc.) therapy and as the tools for target validation in the area of drug discovery. There are already many liposomal reagents for transfection, and some clinical trials are performed using liposomes. It is considered that liposomes, the membrane–structure particles, have unlimited potential in the medical field.

前の記事 次の記事